Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/10/2526 |
| _version_ | 1797515039495684096 |
|---|---|
| author | Alexis Laurent Philippe Abdel-Sayed Nathalie Hirt-Burri Corinne Scaletta Murielle Michetti Anthony de Buys Roessingh Wassim Raffoul Lee Ann Applegate |
| author_facet | Alexis Laurent Philippe Abdel-Sayed Nathalie Hirt-Burri Corinne Scaletta Murielle Michetti Anthony de Buys Roessingh Wassim Raffoul Lee Ann Applegate |
| author_sort | Alexis Laurent |
| collection | DOAJ |
| description | The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration. |
| first_indexed | 2024-03-10T06:39:58Z |
| format | Article |
| id | doaj.art-e602e24b99174b548bd9e2dd93cb5529 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T06:39:58Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-e602e24b99174b548bd9e2dd93cb55292023-11-22T17:45:02ZengMDPI AGCells2073-44092021-09-011010252610.3390/cells10102526Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative MedicineAlexis Laurent0Philippe Abdel-Sayed1Nathalie Hirt-Burri2Corinne Scaletta3Murielle Michetti4Anthony de Buys Roessingh5Wassim Raffoul6Lee Ann Applegate7Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, SwitzerlandRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, SwitzerlandRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, SwitzerlandRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, SwitzerlandRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, SwitzerlandChildren and Adolescent Surgery Service, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, SwitzerlandRomand Burn Center, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, SwitzerlandRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, SwitzerlandThe objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration.https://www.mdpi.com/2073-4409/10/10/2526active pharmaceutical ingredientcell bankingcell therapyCOVID-19diploid progenitor cellsinflammatory lung disease |
| spellingShingle | Alexis Laurent Philippe Abdel-Sayed Nathalie Hirt-Burri Corinne Scaletta Murielle Michetti Anthony de Buys Roessingh Wassim Raffoul Lee Ann Applegate Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine Cells active pharmaceutical ingredient cell banking cell therapy COVID-19 diploid progenitor cells inflammatory lung disease |
| title | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
| title_full | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
| title_fullStr | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
| title_full_unstemmed | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
| title_short | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
| title_sort | evolution of diploid progenitor lung cell applications from optimized biotechnological substrates to potential active pharmaceutical ingredients in respiratory tract regenerative medicine |
| topic | active pharmaceutical ingredient cell banking cell therapy COVID-19 diploid progenitor cells inflammatory lung disease |
| url | https://www.mdpi.com/2073-4409/10/10/2526 |
| work_keys_str_mv | AT alexislaurent evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT philippeabdelsayed evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT nathaliehirtburri evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT corinnescaletta evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT muriellemichetti evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT anthonydebuysroessingh evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT wassimraffoul evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT leeannapplegate evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine |